---
document_datetime: 2025-12-29 11:28:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/orladeyo.html
document_name: orladeyo.html
version: success
processing_time: 0.1124771
conversion_datetime: 2025-12-31 03:48:19.115271
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Orladeyo

[RSS](/en/individual-human-medicine.xml/67434)

##### Authorised

This medicine is authorised for use in the European Union

berotralstat Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Orladeyo](#news-on)
- [More information on Orladeyo](#more-information-on-orladeyo-935)
- [More information on Orladeyo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Orladeyo is a medicine used to prevent attacks of hereditary angioedema (swelling) in patients from 12 years of age. Patients with hereditary angioedema have attacks of rapid swelling such as in the face, throat, arms and legs, or around the gut.

Hereditary angioedema is rare, and Orladeyo was designated an 'orphan medicine' (a medicine used in rare diseases) on 27 June 2018. Further information on the orphan designation can be found [here](/en/medicines/human/orphan-designations/eu-3-18-2028) .

Orladeyo contains the active substance berotralstat.

Expand section

Collapse section

## How is Orladeyo used?

Orladeyo is available as capsules and can only be obtained with a prescription. The recommended dose is one 150-mg capsule daily taken with food.

For more information about using Orladeyo, see the package leaflet or contact your healthcare provider.

## How does Orladeyo work?

The active substance in Orladeyo, berotralstat, works by blocking the activity of a protein called kallikrein. In patients with angioedema, overactive kallikrein leads to raised levels of another protein, bradykinin. Bradykinin is involved in a process that causes blood vessels to widen and become leaky. resulting in the swelling and inflammation of angioedema attacks. Blocking the activity of kallikrein reduces the number of these attacks.

## What benefits of Orladeyo have been shown in studies?

Orladeyo was effective at preventing attacks of angioedema in one main study of 121 patients with hereditary angioedema. Patients taking 150 mg Orladeyo every day for 24 weeks had an average of 1.3 attacks per month, compared with 2.4 attacks per month in patients taking placebo (a dummy treatment).

## What are the risks associated with Orladeyo?

The most common side effects with Orladeyo (which may affect more than 1 in 10 people) are headache, abdominal (belly) pain and diarrhoea. Abdominal pain and diarrhoea, which can occur about 1 to 3 months after starting Orladeyo, get better as treatment continues.

For the full list of side effects and restrictions with Orladeyo, see the package leaflet.

## Why is Orladeyo authorised in the EU?

Orladeyo is effective at reducing the number of angioedema attacks, including life-threatening throat swelling. The medicine can be taken by mouth and its side effects were manageable. The European Medicines Agency therefore decided that Orladeyo's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Orladeyo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Orladeyo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Orladeyo are continuously monitored. Side effects reported with Orladeyo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Orladeyo

Orladeyo received a marketing authorisation valid throughout the EU on 30 April 2021.

Orladeyo : EPAR - Medicine overview

Reference Number: EMA/171246/2021

English (EN) (94.24 KB - PDF)

**First published:** 01/06/2021

**Last updated:** 01/06/2021

[View](/en/documents/overview/orladeyo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-728)

български (BG) (129.16 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/bg/documents/overview/orladeyo-epar-medicine-overview_bg.pdf)

español (ES) (106.77 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/es/documents/overview/orladeyo-epar-medicine-overview_es.pdf)

čeština (CS) (127.59 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/cs/documents/overview/orladeyo-epar-medicine-overview_cs.pdf)

dansk (DA) (105.79 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/da/documents/overview/orladeyo-epar-medicine-overview_da.pdf)

Deutsch (DE) (109.19 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/de/documents/overview/orladeyo-epar-medicine-overview_de.pdf)

eesti keel (ET) (95.82 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/et/documents/overview/orladeyo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (130.44 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/el/documents/overview/orladeyo-epar-medicine-overview_el.pdf)

français (FR) (107.94 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/fr/documents/overview/orladeyo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (125.8 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/hr/documents/overview/orladeyo-epar-medicine-overview_hr.pdf)

italiano (IT) (106.28 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/it/documents/overview/orladeyo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (136.63 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/lv/documents/overview/orladeyo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (128.75 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/lt/documents/overview/orladeyo-epar-medicine-overview_lt.pdf)

magyar (HU) (126.43 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/hu/documents/overview/orladeyo-epar-medicine-overview_hu.pdf)

Malti (MT) (143.79 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/mt/documents/overview/orladeyo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (106.4 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/nl/documents/overview/orladeyo-epar-medicine-overview_nl.pdf)

polski (PL) (129.89 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/pl/documents/overview/orladeyo-epar-medicine-overview_pl.pdf)

português (PT) (107.12 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/pt/documents/overview/orladeyo-epar-medicine-overview_pt.pdf)

română (RO) (127.14 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/ro/documents/overview/orladeyo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (127.62 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/sk/documents/overview/orladeyo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (126.3 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/sl/documents/overview/orladeyo-epar-medicine-overview_sl.pdf)

Suomi (FI) (105.66 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/fi/documents/overview/orladeyo-epar-medicine-overview_fi.pdf)

svenska (SV) (105.44 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

01/06/2021

[View](/sv/documents/overview/orladeyo-epar-medicine-overview_sv.pdf)

Orladeyo : EPAR - Risk-management-plan summary

English (EN) (178.31 KB - PDF)

**First published:** 01/06/2021

**Last updated:** 01/08/2024

[View](/en/documents/rmp-summary/orladeyo-epar-risk-management-plan-summary_en.pdf)

## Product information

Orladeyo: EPAR - Product information

English (EN) (393.6 KB - PDF)

**First published:** 01/06/2021

**Last updated:** 23/09/2024

[View](/en/documents/product-information/orladeyo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-710)

български (BG) (392 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/bg/documents/product-information/orladeyo-epar-product-information_bg.pdf)

español (ES) (325.19 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/es/documents/product-information/orladeyo-epar-product-information_es.pdf)

čeština (CS) (370.84 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/cs/documents/product-information/orladeyo-epar-product-information_cs.pdf)

dansk (DA) (360.69 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/da/documents/product-information/orladeyo-epar-product-information_da.pdf)

Deutsch (DE) (338.51 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/de/documents/product-information/orladeyo-epar-product-information_de.pdf)

eesti keel (ET) (322.63 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/et/documents/product-information/orladeyo-epar-product-information_et.pdf)

ελληνικά (EL) (401.83 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/el/documents/product-information/orladeyo-epar-product-information_el.pdf)

français (FR) (334.93 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/fr/documents/product-information/orladeyo-epar-product-information_fr.pdf)

hrvatski (HR) (433.13 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/hr/documents/product-information/orladeyo-epar-product-information_hr.pdf)

íslenska (IS) (332.21 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/is/documents/product-information/orladeyo-epar-product-information_is.pdf)

italiano (IT) (390.87 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/it/documents/product-information/orladeyo-epar-product-information_it.pdf)

latviešu valoda (LV) (368.59 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/lv/documents/product-information/orladeyo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (388.86 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/lt/documents/product-information/orladeyo-epar-product-information_lt.pdf)

magyar (HU) (400.83 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/hu/documents/product-information/orladeyo-epar-product-information_hu.pdf)

Malti (MT) (417.79 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/mt/documents/product-information/orladeyo-epar-product-information_mt.pdf)

Nederlands (NL) (410.54 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/nl/documents/product-information/orladeyo-epar-product-information_nl.pdf)

norsk (NO) (339.97 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/no/documents/product-information/orladeyo-epar-product-information_no.pdf)

polski (PL) (392.66 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/pl/documents/product-information/orladeyo-epar-product-information_pl.pdf)

português (PT) (302.3 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/pt/documents/product-information/orladeyo-epar-product-information_pt.pdf)

română (RO) (390.01 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/ro/documents/product-information/orladeyo-epar-product-information_ro.pdf)

slovenčina (SK) (401.83 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/sk/documents/product-information/orladeyo-epar-product-information_sk.pdf)

slovenščina (SL) (403.93 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/sl/documents/product-information/orladeyo-epar-product-information_sl.pdf)

Suomi (FI) (327.38 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/fi/documents/product-information/orladeyo-epar-product-information_fi.pdf)

svenska (SV) (289.51 KB - PDF)

**First published:**

01/06/2021

**Last updated:**

23/09/2024

[View](/sv/documents/product-information/orladeyo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00010930/202312 19/09/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Orladeyo : EPAR - All authorised presentations

English (EN) (7.14 KB - PDF)

**First published:** 01/06/2021

[View](/en/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-655)

български (BG) (26.65 KB - PDF)

**First published:**

01/06/2021

[View](/bg/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_bg.pdf)

español (ES) (5.8 KB - PDF)

**First published:**

01/06/2021

[View](/es/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (12.97 KB - PDF)

**First published:**

01/06/2021

[View](/cs/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (5.66 KB - PDF)

**First published:**

01/06/2021

[View](/da/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (5.7 KB - PDF)

**First published:**

01/06/2021

[View](/de/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (5.88 KB - PDF)

**First published:**

01/06/2021

[View](/et/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (25.49 KB - PDF)

**First published:**

01/06/2021

[View](/el/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_el.pdf)

français (FR) (5.69 KB - PDF)

**First published:**

01/06/2021

[View](/fr/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (12.26 KB - PDF)

**First published:**

01/06/2021

[View](/hr/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (6.76 KB - PDF)

**First published:**

01/06/2021

[View](/is/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (5.75 KB - PDF)

**First published:**

01/06/2021

[View](/it/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (22.42 KB - PDF)

**First published:**

01/06/2021

[View](/lv/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (23.19 KB - PDF)

**First published:**

01/06/2021

[View](/lt/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (18.73 KB - PDF)

**First published:**

01/06/2021

[View](/hu/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (19.69 KB - PDF)

**First published:**

01/06/2021

[View](/mt/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (5.73 KB - PDF)

**First published:**

01/06/2021

[View](/nl/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (5.6 KB - PDF)

**First published:**

01/06/2021

[View](/no/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_no.pdf)

polski (PL) (21.93 KB - PDF)

**First published:**

01/06/2021

[View](/pl/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_pl.pdf)

português (PT) (5.74 KB - PDF)

**First published:**

01/06/2021

[View](/pt/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_pt.pdf)

română (RO) (20.93 KB - PDF)

**First published:**

01/06/2021

[View](/ro/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (12.79 KB - PDF)

**First published:**

01/06/2021

[View](/sk/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (12.25 KB - PDF)

**First published:**

01/06/2021

[View](/sl/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (5.6 KB - PDF)

**First published:**

01/06/2021

[View](/fi/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (5.74 KB - PDF)

**First published:**

01/06/2021

[View](/sv/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Orladeyo Active substance berotralstat dihydrochloride International non-proprietary name (INN) or common name berotralstat Therapeutic area (MeSH) Angioedemas, Hereditary Anatomical therapeutic chemical (ATC) code B06AC

### Pharmacotherapeutic group

Other hematological agents

### Therapeutic indication

Orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.

## Authorisation details

EMA product number EMEA/H/C/005138

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

BioCryst Ireland Limited

Rocktwist House, Block 1

Opinion adopted 25/02/2021 Marketing authorisation issued 30/04/2021 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Orladeyo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (184.02 KB - PDF)

**First published:** 12/07/2021

**Last updated:** 23/09/2024

[View](/en/documents/procedural-steps-after/orladeyo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Orladeyo-H-C-PSUSA-00010930-202312 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/332675/2024

English (EN) (124.19 KB - PDF)

**First published:** 23/09/2024

[View](/en/documents/scientific-conclusion/orladeyo-h-c-psusa-00010930-202312-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Orladeyo-H-C-5138-P46-005 : EPAR - Assessment report

Adopted

Reference Number: EMA/212998/2023

English (EN) (798.97 KB - PDF)

**First published:** 12/07/2023

[View](/en/documents/variation-report/orladeyo-h-c-5138-p46-005-epar-assessment-report_en.pdf)

Orladeyo-H-C-5138-P46-004 : EPAR - Assessment report

Adopted

Reference Number: EMA/63140/2023

English (EN) (813.48 KB - PDF)

**First published:** 13/02/2023

[View](/en/documents/variation-report/orladeyo-h-c-5138-p46-004-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Orladeyo : Orphan designation withdrawal assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000045564

English (EN) (414.12 KB - PDF)

**First published:** 01/06/2021

[View](/en/documents/orphan-maintenance-report/orladeyo-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

Orladeyo : EPAR - Public assessment report

Adopted

Reference Number: EMA/153239/2021

English (EN) (8.66 MB - PDF)

**First published:** 01/06/2021

[View](/en/documents/assessment-report/orladeyo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Orladeyo

Adopted

Reference Number: EMA/CHMP/86405/2021

English (EN) (89.51 KB - PDF)

**First published:** 26/02/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-orladeyo_en.pdf)

#### News on Orladeyo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2021) 26/02/2021

#### More information on Orladeyo

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-18-2028) on 27 June 2018. The product was withdrawn from the Union Register of orphan medicinal products by the European Commission in March 2021 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### More information on Orladeyo

- [EMEA-002449-PIP02-18-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002449-pip02-18-m02)
- [Non-Interventional Post-Authorisation Study to Evaluate the Safety, Tolerability and Effectiveness of Berotralstat for Patients with Hereditary Angioedema (HAE) in a Real-World Setting (APeX-N) - post-authorisation study](https://catalogues.ema.europa.eu/study/43576)

**This page was last updated on** 23/09/2024

## Share this page

[Back to top](#main-content)